End of Life Care: Talking About Hospice

Total Page:16

File Type:pdf, Size:1020Kb

End of Life Care: Talking About Hospice Geriatrics Board Review Daniel Pound, MD Clinical Professor Family and Community Medicine, UCSF Medical Director, UCSF Center for Geriatric Care Doe wat je t’liefste doet Carolina Origins Emma Zuletta Otersen 1886 - 1976 Outline Dementia, delirium, and depression Falls, osteopenia, and osteoporosis Hearing and functional impairment Urinary incontinence Age related changes in drug metabolism Medication prescribing with CKD Welcome to Medicare Mrs. Jones 65 yr old retired teacher Diabetes HTN CHF atrial fib GERD Complains about husband’s hearing Mr. Jones 65 yr retired airplane mechanic BPH insomnia anxiety URI symptoms Hard to hear women or to hear in crowds Not bothered by hearing loss Which do you expect? Sensorineural loss Conductive loss Air = bone Air < bone Types of hearing loss Sensorineural Conductive Age related presbycusis Obstructed canal Gradual onset Perforated or scarred TM Effect of noise exposure Otitis media High frequency (♀ voice) Worse in crowds Air = bone on audiogram Air < bone on audiogram Prescribe hearing aid or Treat underlying cause cochlear implant Consonants or Vowels? He has mixed hearing loss Sensorineural: curve slopes down to the right (high frequency) Conductive: air (O) worse than bone (X) conduction Treat conductive loss: Remove cerumen Antibiotic for otitis media Hearing aids His sensorineural loss persists after abx Hearing loss is socially isolating Is patient is likely to use hearing aids? Yes: if patient is bothered by hearing loss No: if only his wife is bothered by hearing loss Side effects: discomfort, feedback, stigma No interventions proven to increase use Cochrane Database Syst Rev. 2014;7:CD010342. Why Hearing Aids Don’t Work Incontinence Mr. Jones has recent onset urine leakage Unpredictable leak day and night x 4 days Lower abdominal pain, no dysuria or fever Hydrocodone PRN back pain Diphenhydramine/pseudoephedrine OTC Guaifenesin with codeine PRN cough What type incontinence? Urge Stress Mixed urge/stress Obstructive overflow Atonic overflow Functional Keys = dribbling, BPH, opioid, cold meds PVR > 200 cc = Overflow Overflow etiology: two types Too little tone Too much tone Neuropathy Opioid Bladder tone Anticholinergic atonic BPH Sphincter tone Alpha agonist obstructive Overflow treatment to tone to tone Atonic Bladder tone Stop codeine Stop Benadryl Bethanechol? Obstructive Stop decongestant Sphincter tone Alpha blocker Finasteride Foley TURP? Mrs. Jones What Type Incontinence? Mrs. Jones has chronic incontinence Leaks urine with cough or sneeze “Can’t get to the bathroom in time” G1P1 vaginal birth PVR 15 cc (normal is < 100 cc) Keys = parous, Valsalva, urgency Mixed urge + stress etiology Too little tone Too much tone Overactive bladder Dementia, UTI? Bladder tone Bladder stone, tumor urge Vaginal birth Prolapse Sphincter tone TURP, alpha blocker stress Mixed incontinence treatment to tone to tone Urge Anticholinergic Bladder tone (oxybutynin) Sympathomimetic (mirabegron $$$) Stress Sphincter tone Kegel exercises Pessary ♀ Urethral sling surgery Anticholinergic Choices Oxybutynin (Ditropan) and tolterodine (Detrol) best studied in elderly Sustained release or patch less side effects Newer M3 selective rx still cause dry mouth Trospium (Sanctura) Solifenacin (Vesicare) Darifenacin (Enablex) Tricyclic (nortriptyline, imipramine) side effects harder for elderly to tolerate Functional incontinence Too little to function Dementia Cognition functional functional Poor vision Prompted voiding Vision (timed voiding) functional Bedside commode Slow gait Urinal Poor dexterity External catheter ♂ Mobility Restraints Sweat pants functional No restraints Urinary Incontinence Too little Too much tone tone Atonic Neuropathy Overactive bladder Bladder Spinal cord disease Dementia Urge Anticholinergics Bladder stone Overflow Opioids Bladder tumor tone PVR < 100 cc PVR > 200 cc Mirabegron Bethanechol Childbirth BPH Sphincter- Prolapse Urethral stricture Obstructive Stress Prostate surgery Prostate cancer outlet Alpha blocker Alpha agonist Overflow PVR < 100 cc Finasteride Pessary PVR > 200 cc tone Foley catheter Bladder sling surgery Bedside commode Poor gait Urinal Poor vision Cognition- External catheter Functional Poor dexterity Sweat pants mobility Poor cognition Prompted voiding Bone Health Mrs. Jones asks about bone density test FH mother died in SNF after hip fracture Menopause age 48 (i.e., not early) DEXA at age 50 was low normal T - 0.9 No prior fractures, smoking, or steroids 3 drinks per day, Caucasian race 5’ 6” 135 lb. BMI 21 Who to screen National Osteoporosis Foundation Women > 65 and men > 70 Postmenopausal women <65 or men 50-70: only if concern based on risk factors USPSTF (for board exams) Women >65 (younger women whose risk >= 65 yr. old white woman w/o other risk factors) Insufficient evidence to recommend for men Medicare DEXA coverage >65 Postmenopausal women Men only if: Osteopenia or vertebral fracture on X-ray Taking or starting steroids Primary hyperparathyroidism Already taking osteoporosis drugs Not covered by Medicare for men just based on prostate cancer therapy Osteoporosis Risk Factors Age Personal history of Gender fracture Low BMI Parental history of hip fracture Current smoking Secondary Alcohol 3 or more drinks per day osteoporosis : Rheumatoid arthritis Low femoral neck Hyperparathyroidism BMD Oral steroid use Her femur neck results Age 50 T -1.0 Normal Age 65 T -1.5 Osteopenia Age 70 T -1.9 Osteopenia Age 75 T -2.5 Osteoporosis Who to treat Osteoporosis Clinical diagnosis (hip or vertebral fracture) DEXA diagnosis (T ≤ - 2.5) Osteopenia (-1 > T > - 2.5) if other risk factors that predict 10-year risk of either: ≥3 % risk of hip fracture, or ≥20 % risk of major osteoporotic fracture These risk rates = cost effective to treat FRAX for osteopenia Age 65 @ 135 lb. 66 inch Age 70 @ 130 lb. 65 inch Her FRAX results Age 50 T -1.0 FRAX N/A (normal DEXA) Age 65 T -1.5 1.5% hip 19% major Age 70 T -1.9 6.5% hip 21% major Age 75 T -2.5 FRAX N/A (osteoporosis) Osteoporosis Treatment Calcium 1200 mg elemental total (incl diet) Ca carbonate inexpensive Ca citrate better absorbed if high gastric pH Vitamin D3 800 – 1000 IU Weight bearing exercise Avoid tobacco and alcohol Fall prevention Osteoporosis drug therapy Bisphosphonate Alendronate (po) or zoledronic acid (IV) Prevent hip + spine fractures Contraindicated if GFR < 30 (po) or 35 (IV) Side effects: Esophagitis (sit up after taking) Musculoskeletal pain Osteonecrosis of jaw (rare) Atypical femur fractures (rare) More expensive therapies Used if intolerant of, contraindication to, or continued fractures with bisphosphonates Denosumab (Prolia) anti-RANKL antibody Prevents hip + spine fractures Subcu Q6mo, caution if GFR < 30 (hypoCa) Teriparatide (Forteo) anabolic PTH Prevents spine + non-spine fractures Not specifically proven to prevent hip fracture Subcu daily x2 years ($72,000 total for 2 yrs) Less attractive therapies Nasal calcitonin Prevents spine fractures, not proven for hip Causes small increased risk for cancer Short term use as analgesic for spine fracture Raloxifene (Evista) SERM Prevents spine fractures, not proven for hip Prevents breast cancer Not used in elderly due to risk for thrombi Her treatment T -1.0 Normal GFR 70 calcium D exercise T -1.5 FRAX 1.5% / 19% GFR 55 same T -1.9 FRAX 6.5% / 21% GFR 40 add bisphosphonate for % risk T -2.5 Osteoporosis GFR 25 stop bisphosphonate for GFR Mr. Jones falls Falls getting up from bed to toilet at night Minor injuries Diazepam, hydrocodone, or Flexeril (cyclobenzaprine) PRN back pain Zolpidem PRN insomnia Terazosin at bed time Multifactorial and Serious Intrinsic causes Extrinsic causes Abnl gait/balance Environment hazards Weakness Medications Neuropathy Vestibular Precipitating factors Orthostatic ↓BP Syncope Vision loss Acute illness 10% risk major injury 2% risk death Medicines That Cause Falls Sedation Orthostatic hypotension Opioids Antihypertensives Benzodiazepines Alpha blockers for BPH Other sleeping pills Nitrates Antipsychotics Antipsychotics Antidepressants Tricyclics Antiemetics Trazodone Antihistamines Anticholinergics Muscle relaxers Antiparkinsonian Fall Interventions PT for strength + balance Tai Chi (strength + balance) Stop psychotropic rx Address home hazards Multifactorial assessment Cataract surgery x1 for poor vision Vitamin D 800 IU/day per USPSTF Emergency Response Alert Texting For Seniors BFF = Best Friend Fell FWIW = Forgot Where I Was TTML = Talk To Me Louder ROFLACGU = Rolling On Floor Laughing And Can’t Get Up His Fall Prevention Plan Refer PT Change terazosin to tamsulosin Vision 20/50 eye exam for cataracts Reduce or stop sedating medications Avoid diazepam (Valium) in elderly Fat soluble half-life 4-5 days Avoid muscle relaxers (SOMA or Flexeril) Excess sedation >> minimal pain relief Mrs. Jones falls Falls going up step from garage to kitchen Painful buttock hematoma, no head bleed Daughter flies in from LA, reports she is unsteady, confused, has urine odor 80 yr 115 lb. 64 inches 19.7 BMI 108/55 Meds glyburide, oxybutynin, famotidine, clonidine, digoxin 0.25mg, apixaban, alendronate creatinine 1.9 A1C 6.8 Precipitating causes of fall Rx acute illness (UTI ↓ functional reserve) Check for orthostatic hypotension Supine vs standing up x3 minutes Systolic ↓ 20 or diastolic ↓10 = abnormal Elderly
Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Updatirg the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
    Updatirg the BeersCriteria for Potentially InappropriateMedication Use in Older Adults Resultsof a US ConsensusPanel of Experts DonnaM.Fich,PhD,RN;lamesW.Cooper,PhD,RPh;WilliamE.Wade,PhannD,FASHP,FCCP; JenniJerL. Waller, PhD;J, RossMaclean, MD; Marh H. Beers,MD Bcckground: Medication toxic effectsand drug- Reruhr: This study identified 48 individual medica- relatedproblems can have profound medical and safety tions or classeso[ medicationsto avoid in older adults consequencesfor older adults and economically affect the and their potential concernsand 20 diseases/conditions health caresystem. The purpose of this initiative was to and medicationsto be avoidedin older adultswith these reviseand update the Beerscriteria for potentially inap- conditions.Of thesepotentially inappropriate drugs, 66 propriate medicationuse in adults 65 yearsand older in wereconsidered by the panelto haveadverse outcomes the United States. of high severity. lYlcthcdr: This study used a modified Delphi method, a Concludonr: This study is an importantupdate of pre- setof proceduresand methodsfor formulating a groupjudg- viously establishedcriteria that have been widely used ment for a subject matter in which precise information is and cited. The application of the Beerscriteria and other Iacking. The criteria reviewed covered 2 types of state- tools for identifying potentially inapproprlate medica- ments: (l) medicationsor medicationclasses that should tion use will continue to enableproviders to plan inter- grnerally be avoidedin persons 65 years or older because
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • 170 Limited Use of Anticholinergic Drugs For
    170 Penning-van Beest F1, Sukel M1, Reilly K2, Kopp Z2, Erkens J1, Herings R1 1. PHARMO Institute, 2. Pfizer Inc LIMITED USE OF ANTICHOLINERGIC DRUGS FOR OVERACTIVE BLADDER: A PHARMO STUDY Hypothesis / aims of study The aim of the study was to determine the prevalence of use of anticholinergic drugs for overactive bladder (OAB) in men and women in the Netherlands in the period 1998-2003. Study design, materials and methods Data were obtained from the PHARMO Record Linkage System, which includes patient centric data of drug-dispensing records and hospital records of more than one million patients in the Netherlands. Currently four anticholinergic drugs are available on the Dutch market for the treatment of OAB: tolterodine immediate release (IR), since 1998, tolterodine extended release (ER), since 2001, oxybutynin, since 1986, and flavoxate, since 1979. All patients who were ever prescribed these OAB drugs in the period January 1998 until December 2003 were included in the study cohort. The prevalence of use of tolterodine ER, tolterodine IR, oxybutynin and flavoxate was determined per calendar year, stratified by gender, by counting the number of patients having a dispensing with a duration of use including a single fixed day a year. Results The number of OAB drug users included in the study cohort increased from about 3,800 in 1998 to 5,000 in 2003. About 60% of the OAB drug users in the study cohort were women and about 42% of the OAB drug users were 70 years or older. The use of OAB drugs increased from 100 users per 100,000 men in 1998 to 140 users per 100,000 men in 2003 (table).
    [Show full text]
  • Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’
    0270.6474/85/0505-1202$02.00/O The Journal of Neuroscience CopyrIght 0 Society for Neuroscrence Vol. 5, No. 5, pp. 1202-1207 Printed in U.S.A. May 1985 Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’ EDWIN M. MEYER* AND DEBORAH H. OTERO Department of Pharmacology and Therapeutics, University of Florida School of Medicine, Gainesville, Florida 32610 Abstract brain (Gonzales and Crews, 1984). M,-receptors, however, appear pre- and postsynaptically in brain, are regulated by an intrinsic The muscarinic receptors that modulate acetylcholine membrane protein that binds to GTP (g-protein), and may not be release from rat cortical synaptosomes were characterized coupled to changes in phosphatidylinositol turnover. with respect to sensitivity to drugs that act selectively at M, The present studies were designed to determine whether M,- or or Ma receptor subtypes, as well as to changes in ionic Mp-receptors mediate the presynaptic modulation of ACh release. strength and membrane potential. The modulatory receptors These studies involve dose-response curves for the release of appear to be of the M2 type, since they are activated by synaptosomal [3H]ACh in the presence of selected muscarinic ago- carbachol, acetylcholine, methacholine, oxotremorine, and nists and antagonists, as well as treatments that selectively alter MI- bethanechol, but not by pilocarpine, and are blocked by or M,-receptor activity. Our results indicate that the presynaptic atropine, scopolamine, and gallamine (at high concentra- modulation of [3H]ACh release is mediated by MP- but not MI- tions), but not by pirenzepine or dicyclomine.
    [Show full text]
  • 121 Comparative Evaluation of Human Mucosa And
    121 Oki T1, Luvsandorj O1, Suzuki K1, Kageyama A1, Otsuka A2, Shinbo H2, Ozono S2, Yamada S1 1. Department of Pharmacokinetics and Pharmacodynamics, Sch of Pharm Sci, University of Shizuoka, 2. Department of Urology, Hamamatsu University School of Medicine COMPARATIVE EVALUATION OF HUMAN MUCOSA AND DETRUSOR MUSCARINIC RECEPTOR BINDING BY ANTICHOLINERGIC AGENTS IN THE TREATMENT OF OVERACTIVE BLADDER Hypothesis / aims of study The urothelium is the epithelial lining of the urinary tract. Our traditional understanding of the function of this region was simply that of passive barrier between the urinary tract and its contents. In recent years, the urothelium exhibits neuron-like properties that contribute to sensory function. Although the function of such an innervation may be unclear, recent studies in humans and animals have indicated that muscarinic receptors (mAChRs) are present on both mucosa and detrusor of the urinary bladder [1, 2]. The mucosal mAChRs may represent a novel site of action of agents for the treatment of bladder disorders. Anticholinergic agents such as oxybutynin and propiverine are widely used for the treatment of overactive bladder. Tolterodine and darifenacin have been currently developed as novel anticholinergic agents that may exhibit pharmacological selectivity in the bladder. Furthermore, oxybutynin, propiverine and tolterodine are metabolized in the intestine and liver to form active metabolites, N-desethyl-oxybutynin (DEOB), 1- methyl-4-piperidyl benzilate N-oxide (DPr-P-4(N→O)) and 5-hydroxymethyl metabolite (5-HM), respectively. Although these metabolites are assumed to contribute to the mAChR blockade of parent compounds, their mAChR binding characteristics in the mucosa have not been examined.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Anticholinergics for Overactive Bladder Evidence, Clinical Issues and Comparisons
    Anticholinergics for Overactive Bladder Evidence, Clinical Issues and Comparisons RxFiles Academic Detailing Program March 2008 Saskatoon City Hospital 701 Queen Street, Saskatoon, SK S7K 0M7 www.RxFiles.ca Recent Guidelines: Overactive Bladder – Background • Special caution should be used for the elderly who Canadian Urological1: • Overactive bladder (OAB) is also known as urge are especially sensitive to side effects from ACs. Can J Urol. 2006;13(3):3127-38 incontinence and occurs when there is an inability Some with dementia or cognitive impairment may 2 not tolerate ACs at all. If using an AC in the NICE (UK) 2006 : to delay voiding when an urge is perceived. elderly, start at the lowest dose, titrate up and www.nice.org.uk/nicemedia/pdf/CG • OAB is differentiated from stress urinary 40fullguideline.pdf reassess for effectiveness and adverse effects. incontinence (SUI) which is associated with a loss of Remember that many drugs contribute to the total urine secondary to intra-abdominal pressure such as anticholinergic load (e.g. antidepressants, antipsychotics).14 Systematic Reviews: occurs with coughing, sneezing and exercise.9 Cochrane: Hay-Smith J et al. • ACs should not be used with acetylcholinesterase • Anticholinergics (ACs) are useful drugs for Which anticholinergics drug for inhibitors (e.g. ARICEPT, REMINYL, EXELON) given treating OAB, however their use is limited by the overactive bladder symptoms in their opposing mechanisms.23 adults. Cochrane Systematic side effects of dry mouth and constipation. 3 Reviews 2005, Issue 3. 4 Oregon 2005 : Are non-drug treatment options effective? Oxybutynin (Oxy) vs Tolterodine (Tol) • A Cochrane systematic review found 3: www.ohsu.edu/drugeffectiveness/rep • Bladder training (a gradual time lengthening orts/documents/OAB%20Final%20 no statistically significant differences for Report%20Update%203.pdf between voids) or urge suppression may be useful 10 patient perceived improvement, leakage Canada in OAB, especially in addition to ACs.
    [Show full text]
  • CONTRAINDICATIONS ------Pediatric Patients (486 on DETROL LA, 224 on Placebo) Is Available
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Controlled Narrow-Angle Glaucoma: use caution in patients being These highlights do not include all the information needed to use Detrol® treated for narrow-angle glaucoma. (5.3) LA safely and effectively. See full prescribing information for Detrol LA. • Myasthenia Gravis: use caution in patients with myasthenia gravis. (5.6) • QT Prolongation: Consider observations from the thorough QT study in ® Detrol LA (tolterodine tartrate extended release capsules) clinical decisions to prescribe DETROL LA to patients with a known For oral administration history of QT prolongation or to patients who are taking Class IA (e.g., Initial U.S. Approval: December 2000 quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications (5.7) ----------------------------INDICATIONS AND USAGE--------------------------- Detrol LA is an antimuscarinic indicated for the treatment of overactive ------------------------------ADVERSE REACTIONS------------------------------- bladder with symptoms of urge urinary incontinence, urgency, and frequency. The most common adverse reactions (incidence >4% and >placebo) were dry (1) mouth , headache, constipation and abdominal pain. (6.1) ----------------------DOSAGE AND ADMINISTRATION----------------------- • 4 mg capsules taken orally once daily with water and swallowed To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at whole. (2.1) 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. • 2 mg capsules taken orally once daily with water and swallowed whole in the presence of: ------------------------------DRUG INTERACTIONS------------------------------- o mild to moderate hepatic impairment (Child-Pugh • Potent CYP3A4 inhibitors: Co-administration may increase systemic class A or B) (2.2) exposure to DETROL LA. Reduce DETROL LA dose to 2 mg once o severe renal impairment [Creatinine Clearance (CCr) daily.
    [Show full text]
  • Supplemental Table 1: Patient Characteristics, Interventions and Definitions/Variables of Persistence, Adherence and Discontinuation Reported in the Studies
    Adherence and persistence to OAB medication Supplemental Table 1: Patient characteristics, interventions and definitions/variables of persistence, adherence and discontinuation reported in the studies. Author (year) and Definition of persistence/adherence/discontinuation and Length of country (database) Participants Drug/intervention* independent variables on persistence follow-up Brostrøm and Hallas n=2477 Any prescription of OAB Patients who continued taking a particular drug for up to 7 years with Up to 7 (2009)1 Male: n=836 (33.8%) medication: no more than 120-day gaps were regarded as experiencing single- years Odense University Female: n=1641 (66.2%) flavoxate (n=21) treatment episodes Pharmacoepidemio- Mean age: 68.3 yearsa oxybutynin TD (n=48) logical Database tolterodine (n=1478) Variables: age, gender, prior use of OAB agents and use of (OPED); Denmark) solifenacin (n=774) anti-diabetic drugs (1999–2006) trospium (n=271) darifenacin (n=52) Chancellor et al (2013)2 n=103 250 First (new) prescription of OAB To be considered a discontinuation, patients were required to have a 2 years IMS Lifelink Database, Male: n≈25 916a (25.1%) medication in adults ≥18 years: gap of at least 45 days in therapy based on fill dates and days’ Connecticut; USA Female: n≈77 334a (74.9%) tolterodine ER (n=43 881)a supply (2005–2008) Mean (SD) age: 58.7 (15.7) solifenacin (n=15 488)a years oxybutynin (n=15 075)a Adherence rate was defined as the proportion of patients filling more darifenacin (n=10 532)a than one prescription with an MPR of ≥80% oxybutynin
    [Show full text]
  • BETHANECHOL CHLORIDE TABLETS, USP5 Mg, 10 Mg, 25 Mg
    BETHANECHOL CHLORIDE- bethanechol chloride tablet Upsher-Smith Laboratories, LLC ---------- BETHANECHOL CHLORIDE TABLETS, USP 5 mg, 10 mg, 25 mg and 50 mg Rx only DESCRIPTION Bethanechol chloride, USP, a cholinergic agent, is a synthetic ester which is structurally and pharmacologically related to acetylcholine. It is designated chemically as 2-[(aminocarbonyl)oxy]-N, N, N-trimethyl-1-propanaminium chloride. Its molecular formula is C7H17ClN2O2 and its structural formula is: It is a white, hygroscopic crystalline powder having a slight amine-like odor, freely soluble in water, and has a molecular weight of 196.68. Each tablet for oral administration contains 5 mg, 10 mg, 25 mg or 50 mg bethanechol chloride, USP. Tablets also contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, (25 mg and 50 mg) D&C Yellow #10 Lake and FD&C Yellow #6 Lake. CLINICAL PHARMACOLOGY Bethanechol chloride acts principally by producing the effects of stimulation of the parasympathetic nervous system. It increases the tone of the detrusor urinae muscle, usually producing a contraction sufficiently strong to initiate micturition and empty the bladder. It stimulates gastric motility, increases gastric tone and often restores impaired rhythmic peristalsis. Stimulation of the parasympathetic nervous system releases acetylcholine at the nerve endings. When spontaneous stimulation is reduced and therapeutic intervention is required, acetylcholine can be given, but it is rapidly hydrolyzed by cholinesterase and its effects are transient. Bethanechol chloride is not destroyed by cholinesterase and its effects are more prolonged than those of acetylcholine. Effects on the GI and urinary tracts sometimes appear within 30 minutes after oral administration of bethanechol chloride, but more often 60 to 90 minutes are required to reach maximum effectiveness.
    [Show full text]